Ads
related to: monoclonal antibody treatment prostate cancer results chart by year timeline- Understand Your Results
Learn About Tests And Scans Used
To Diagnose And Monitor PC.
- Support Your Loved Ones
Explore Resources And Get Guidance
On How To Care For Someone With PC.
- Cancer Progression
Understand The Different Kinds Of
Prostate Cancer & Its Progression.
- Patient Story Videos
Watch Real Stories Of Patients
Who Have Battled Prostate Cancer.
- Understand Your Results
Search results
Results from the WOW.Com Content Network
2010 – US FDA approves immunotherapy, sipuleucel-T dendritic cell vaccine for advanced prostate cancer [12] 2010 – China advances cryoimmunotherapy to treat breast, kidney, lung, liver, prostate and bone cancer [44] [45] [46] 2011 – US FDA approves monoclonal antibody, Ipilimumab for advanced melanoma [12]
It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen. [1] Adecatumumab has been used in clinical studies of treatment in colorectal, prostate [2] and breast cancers. [3] Phase II results were published ...
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. [1] [2]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). [18] Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
Prostate cancer: Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy Docetaxel: IV: As above. Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.
Antibody-directed enzyme prodrug therapy (ADEPT) involves the application of cancer-associated monoclonal antibodies that are linked to a drug-activating enzyme. Systemic administration of a non-toxic agent results in the antibody's conversion to a toxic drug, resulting in a cytotoxic effect that can be targeted at malignant cells.
Durvalumab, [8] sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. [6] It was developed by Medimmune / AstraZeneca . [ 9 ] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ).
Ads
related to: monoclonal antibody treatment prostate cancer results chart by year timeline